...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Epigenetic Therapeutic Targets Virtual Summit Presentation July 28, 2020

On July 28, 2020, Zenith participated in the Epigenetic Therapeutic Targets Virtual Summit, with an oral presentation by Dr. Eric Campeau, titled: "Design of combination strategies and identification of biomarkers associated with clinical response to ZEN-3694 in combination with enzalutamide in mCRPC."

https://www.zenithepigenetics.com/upload/media_element/122/01/zenith-epigenetic-therapeutic-targets-2020-final.pdf

Share
New Message
Please login to post a reply